Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C85444
http://purl.obolibrary.org/obo/NCIT_C85444
|
|---|---|
| Preferred Name | Tivozanib |
| Definitions |
An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis. |
|---|---|
| prefLabel | Tivozanib
|
| label | Tivozanib
|
| Has_Salt_Form | |
| code | C85444
|
| Has_Target | |
| prefixIRI | NCIT:C85444
|
| in_subset |
See more
See less
|
| Display_Name | Tivozanib
|
| Preferred_Name | Tivozanib
|
| FDA_UNII_Code | 172030934T
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C22H19ClN4O5
|
| Maps_To | Tivozanib
|
| CAS_Registry | 475108-18-0
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2827667
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |